TICKERNERD
Menu
LUNGLUNGHealthcare · Medical Devices

LUNG Stock Forecast: Pulmonx Corp. Price Predictions for 2026-2027

Last close, 6 Aug 2026
$2.05
+3.54% on the day

The 5 Wall Street analysts covering Pulmonx Corp. hold a median 12-month price target of $3 — +46.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 77 of 100 as at 6 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$87.0M
Ticker Nerd rank
77 / 100
Median analyst target
$3.00
Analysts covering
5
Total return, dividends reinvested
1W
+27.3%
1M
+38.5%
YTD
−7.2%
1Y
+27.3%
From 52W high
−21.2%
From 52W low
+75.2%
$1.17
$2.60
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

LUNG stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Pulmonx Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 6 Aug 2026
77 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
88
Growth
86
Accruals
82
Size
77
Issuance
55
Quality
45
Momentum
34
Value
34
Volatility
20

Revisions (88): Analysts have, on balance, been raising their forecasts.

Volatility (20): The share price moves around a lot.

The rank is the raw material. Whether the rules would actually own Pulmonx Corp. — and when they’d sell — is the membership.

Wall Street

LUNG stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LUNG, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00Oct 25Jan 26Apr 26Jul 26LUNGHigh $5.00Median $3.00Low $2.50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says5 analysts
3 Buy2 Hold0 Sell
Low $2.50Median $3.00High $5.00

The green dot is the last close — the median target sits +46.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
30 Apr 2026D. Boral CapitalMaintainsBuy—
30 Apr 2026D. Boral CapitalMaintainsBuy$14
5 Mar 2026Canaccord GenuityMaintainsBuy—
5 Mar 2026D. Boral CapitalMaintainsBuy—
20 Feb 2026D. Boral CapitalMaintainsBuy—
13 Nov 2025D. Boral CapitalMaintainsBuy—
28 Oct 2025D. Boral CapitalMaintainsBuy—
28 Oct 2025Lake StreetMaintainsBuy—
8 Sept 2025D. Boral CapitalMaintainsBuy—
1 Aug 2025Wells FargoMaintainsEqual-Weight—
31 July 2025D. Boral CapitalMaintainsBuy—
31 July 2025Lake StreetMaintainsBuy—
31 July 2025Piper SandlerDowngradeNeutral—
31 July 2025StifelMaintainsBuy—
22 May 2025CitigroupMaintainsNeutral—
1 May 2025Canaccord GenuityMaintainsBuy—
1 May 2025D. Boral CapitalMaintainsBuy—
1 May 2025Piper SandlerReiteratesOverweight—
11 Mar 2025D. Boral CapitalMaintainsBuy—
10 Mar 2025D. Boral CapitalInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

LUNG analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
4
Analysts cutting
0
Fundamentals

Pulmonx Corp. (LUNG) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.5×

Cheaper than 83% of US stocks

Price / sales
1.0×

Cheaper than 71% of US stocks

Price / book
2.1×

Cheaper than 45% of US stocks

EV / EBITDA
−2.0×

Cheaper than 71% of US stocks

Growth & margins
Revenue growth (YoY)
−4.6%

Higher than 21% of US stocks

Earnings growth (YoY)
—
Gross margin
77.9%

Higher than 89% of US stocks

Operating margin
−39.8%

Higher than 19% of US stocks

Net margin
−55.0%

Higher than 9% of US stocks

Returns & dividend
Return on equity
−88.9%

Higher than 14% of US stocks

Return on assets
−22.1%

Higher than 18% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

LUNG vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
LUNGPulmonx Corp.$87.0M
77
SERASera Prognostics, Inc.$78.3M
39
OMOutset Medical, Inc.$95.1M
36
HYPRHyperfine, Inc.$96.2M
53
NNOXNano-X Imaging Ltd.$71.0M
20
RPIDRapid Micro Biosystems, Inc.$103.6M
30
LNSRLENSAR, Inc.$68.4M
37
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LUNG appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest LUNG news & analysis

Pulmonx (LUNG) Upgraded to Buy: What Does It Mean for the Stock?

Zacks Investment Research · 3 Aug 2026positive

Zacks Investment Research upgraded Pulmonx (LUNG) to a Zacks Rank #2 (Buy), citing growing optimism about the company's earnings prospects. The report suggests the stock could move higher on this improved outlook.

Why it matters — Pulmonx watchers would care because the Zacks upgrade reflects improved expectations for the company's earnings trajectory, which can influence how investors view the stock.

Pulmonx Corporation (LUNG) Q2 2026 Earnings Call Transcript

Seeking Alpha · 30 July 2026neutral

Pulmonx Corporation held its Q2 2026 earnings conference call, and a transcript of the call has been published by Seeking Alpha.

Why it matters — Earnings call transcripts provide LUNG watchers with detailed insights into the company's quarterly financial performance and management's outlook.

Pulmonx Q2 Earnings Call Highlights

MarketBeat · 29 July 2026positive

Pulmonx reported second-quarter revenue of $22.8 million and reaffirmed its full-year 2026 revenue outlook. Executives also highlighted progress in rebuilding the U.S. sales organization, reducing operating expenses, and preparing to resume China shipments.

Why it matters — LUNG watchers would care because the company's progress on U.S. sales team rebuilding, expense reduction, and potential return to the Chinese market could shape its near-term performance.

Pulmonx Corporation (LUNG) Reports Q2 Loss, Beats Revenue Estimates

Zacks Investment Research · 29 July 2026positive

Pulmonx reported a Q2 loss of $0.24 per share, narrower than the Zacks Consensus Estimate of a $0.28 loss and improved from the $0.38 loss a year earlier.

Why it matters — The smaller-than-expected loss and year-over-year improvement signal better-than-expected quarterly performance for Pulmonx.

Pulmonx Reports Second Quarter 2026 Financial Results

GlobeNewsWire · 29 July 2026neutral

Pulmonx Corporation reported its financial results for the second quarter of 2026, which ended June 30, 2026. The announcement was made on July 29, 2026, via a press release from GlobeNewsWire.

Why it matters — This quarterly financial report provides LUNG watchers with an update on the company's recent performance and financial health.

FAQ

Frequently asked questions about LUNG stock

What is the LUNG stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Pulmonx Corp. have a median 12-month price target of $3, with estimates ranging from $2.5 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LUNG stock a buy right now?

Of the 5 analysts covering Pulmonx Corp., 3 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Pulmonx Corp. 77 out of 100 across roughly 4,600 US stocks as at 6 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LUNG?

As at 6 Aug 2026, Pulmonx Corp. ranks 77 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (88 of 100).

Will LUNG stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +46.3% from the last close, and Ticker Nerd's factor model ranks Pulmonx Corp. 77 out of 100 as at 6 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LUNG stock forecast for 2030?

No analyst covering Pulmonx Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LUNG are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2.5 to $5 over the next 12 months.

How has LUNG stock performed over the past year?

Pulmonx Corp. returned +27.3% over the 12 months to 6 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Pulmonx Corp. do?

Pulmonx Corporation is a leading medical technology company specializing in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The company focuses on developing and commercializing advanced technologies that offer new options for patients suffering from lung disorders.

What is the latest news on LUNG?

The most recent item we track (Zacks Investment Research, 3 Aug 2026): "Pulmonx (LUNG) Upgraded to Buy: What Does It Mean for the Stock?". Zacks Investment Research upgraded Pulmonx (LUNG) to a Zacks Rank #2 (Buy), citing growing optimism about the company's earnings prospects. The report suggests the stock could move higher on this improved outlook.

Company

About Pulmonx Corp.

Pulmonx Corporation is a leading medical technology company specializing in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The company focuses on developing and commercializing advanced technologies that offer new options for patients suffering from lung disorders. One of its flagship products, the Zephyr Valve, is a tiny device designed for bronchoscopic lung volume reduction in severe emphysema patients, providing an alternative to invasive surgical procedures. Pulmonx's innovative solutions impact the healthcare sector by improving patient outcomes and offering healthcare providers effective, less invasive treatment options. By driving advancements in respiratory care, Pulmonx plays a significant role in the growing medical device industry, particularly within the respiratory segment, as the demand for novel therapeutic options for chronic lung diseases increases. Headquartered in Redwood City, California, the company collaborates with medical professionals worldwide to expand access to its life-changing technologies.

CEO Mr. Steven S. Williamson · 7,859 employees · Japan · https://www.nisshin.nipponsteel.com